Infectious Co-Factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: New insights and interventions

Current HIV Research

Volumn 10, Issue 3, 2012, Pages 228-237

  Barnabas, Ruanne V ^a,b   Celum, Connie ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Epidemiologic synergy; HIV; HIV 1 RNA; HIV 1 viral load; HSV 2; Valacyclovir

Indexed keywords

ACICLOVIR; HERPES SIMPLEX VACCINE; TENOFOVIR; VALACICLOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION SENSITIVITY; MIXED INFECTION; NONHUMAN; PREVALENCE; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

EID: 84861143573     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212800618156     Document Type: Article

References (95)

1. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sexually transmitted diseases [Review] 1992; 19(2): 61-77.
2. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bulletin of the World Health Organization 2008; 86(10): 805-12, A.
3. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2010.
4. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes: the journal of the IHMF [Review] 2004; 11 Suppl 1: 24A-35A.
5. Xu F, Sternberg M, Gottlieb S, et al. Seroprevalence of Herpes Simplex Virus Type 2 Among Persons Aged 14-49 Years - United States, 2005-2008. Morbidity and Mortality Weekly Report 2010, 2010; 59(15): 456-9.
6. Cowan FM, French RS, Mayaud P, et al. Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka. Sexually transmitted infections 2003; 79(4): 286-90.
7. Abu-Raddad LJ, Schiffer JT, Ashley R, et al. HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa. Epidemics 2010; 2(4): 173-82.
8. Bohl DD, Katz KA, Bernstein K, et al. Prevalence and correlates of herpes simplex virus type-2 infection among men who have sex with men, san francisco, 2008. Sexually Transmitted Diseases 2011; 38(7): 617-21.
9. McQuillan GM, Kruszon-Moran D, Granade T, Feldman JW. Seroprevalence of Human Immunodeficiency Virus in the US Household Population Aged 18-49 Years: The National Health and Nutrition Examination Surveys, 1999-2006. J Acquir Immune Defic Syndr 2009.
10. Mugo N, Dadabhai SS, Bunnell R, et al. Prevalence of Herpes Simplex Virus Type 2 Infection, Human Immunodeficiency Virus/Herpes Simplex Virus Type 2 Coinfection, and Associated Risk Factors in a National, Population-Based Survey in Kenya. Sex Transm Dis 2011; 38(11): 1059-66.
11. Schiffer JT, Corey L. Herpes Simplex Virus-2 Infection: New understandings in the dynamics of viral-host interactions and their implications for developing novel antivirals, vaccines and immunotherapies. Nat Med 2011 Under review.
12. Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med [Review]; 59: 381-95.
13. Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. The J Infect Dis 2008; 198(8): 1141-9.
14. [Schiffer JT, Abu-Raddad L, Mark KE, et al. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med 2009; 1(7): 7ra16.
15. Granero GE, Amidon GL. Stability of valacyclovir: implications for its oral bioavailability. Int J Pharm [In Vitro] 2006; 317(1): 14-8.
16. Gupta R, Wald A, Krantz E, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 2004; 190(8): 1374-81.
17. Johnston C, Saracino M, Kuntz S, et al. Ineffectiveness of daily standard and high-dose antiviral therapy in preventing short episodes of genital HSV-2 reactivation: three randomized, openlabel cross-over trials. Lancet 2012; 379: 641-47
18. McClelland RS, Wang CC, Overbaugh J, et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002; 16(18): 2425-30.
19. Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. The Journal of infectious diseases [Comparative Study] 2004; 190(4): 693-6.
20. Ameli N, Bacchetti P, Morrow RA, et al. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006; 20(7): 1051-8.
21. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and metaanalysis of longitudinal studies. Aids 2006; 20(1): 73-83.
22. Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009; 199(7): 958-64.
23. Glynn JR, Carael M, Auvert B, et al. Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia. AIDS 2001; 15 Suppl 4: S51-60.
24. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35(5): 435-45.
25. Mahiane SG, Legeai C, Taljaard D, et al. Transmission probabilities of HIV and herpes simplex virus type 2, effect of male circumcision and interaction: a longitudinal study in a township of South Africa. Aids 2009; 23(3): 377-83.
26. Abu-Raddad LJ, Magaret AS, Celum C, et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One 2008; 3(5): e2230.
27. Celum C, Levine R, Weaver M, Wald A. Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Organ 2004; 82(6): 447-53.
28. Celum CL. The interaction between herpes simplex virus and human immunodeficiency virus Herpes 2004; 11 Suppl 1: 36A-45A.
29. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15(8): 886-92.
30. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280(1): 61-6.
31. Mbopi Keou FX, Gresenguet G, Mayaud P, et al. Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa. AIDS 1999; 13(4): 536-7.
32. Albrecht MA, DeLuca NA, Byrn RA, Schaffer PA, Hammer SM. The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes. J Virol [In Vitro] 1989; 63(5): 1861-8.
33. Golden MP, Kim S, Hammer SM, et al. Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis 1992; 166(3): 494-9.
34. Palu G, Benetti L, Calistri A. Molecular basis of the interactions between herpes simplex viruses and HIV-1. Herpes 2001; 8(2): 50-5.
35. [Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3(77): 77ra29.
36. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342(13): 921-9.
37. Duffus WA, Mermin J, Bunnell R, et al. Chronic herpes simplex virus type-2 infection and HIV viral load. Int J STD AIDS 2005; 16(11): 733-5.
38. [Gray RH, Li X, Wawer MJ, Serwadda D, et al. Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis 2004; 189(7): 1209-15.
39. Mole L, Ripich S, Margolis D, Holodniy M. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis 1997; 176(3): 766-70.
40. Serwadda D, Gray RH, Sewankambo NK, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested casecontrol study in Rakai, Uganda. J Infect Dis 2003; 188(10): 1492-7.
41. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186(12): 1718-25.
42. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV- 1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122(8): 573-9.
43. Barnabas RV, Webb EL, Weiss HA, Wasserheit JN. The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis. AIDS 2011; 25(13): 1559-73.
44. Mayaud P, Legoff J, Weiss HA, et al. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis 2009; 200(2): 216-26.
45. Paz-Bailey G, Sternberg M, Puren AJ, et al. Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial. J Infect Dis 2009; 200(7): 1039-49.
46. Phiri S, Hoffman IF, Weiss HA, et al. Impact of aciclovir on ulcer healing, lesional, genital and plasma HIV-1 RNA among patients with genital ulcer disease in Malawi. Sex Transm Infect 2010; 86(5): 345-52.
47. Weiss HA, Paz Bailey G, Phiri S, et al. Episodic therapy for genital herpes in sub-saharan Africa: a pooled analysis from three randomized controlled trials. PloS one 2011; 6(7): e22601.
48. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1- discordant couples in Rakai, Uganda. Lancet 2001; 357(9263): 1149-53.
49. Chen KT, Segu M, Lumey LH, et al. Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstetrics and gynecology 2005; 106(6): 1341-8.
50. Drake AL, John-Stewart GC, Wald A, et al. Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol 2007; 109(2 Pt 1): 403-9.
51. Bollen LJ, Whitehead SJ, Mock PA, et al. Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission? AIDS 2008; 22(10): 1169-76.
52. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebocontrolled trial. Lancet 2008; 371(9630): 2109-19.
53. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362(5): 427-39.
54. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358(15): 1560-71.
55. Baeten JM, Reid SE, Delany-Moretlwe S, et al. Clinical and Virologic Response to Episodic Acyclovir for Genital Ulcers Among HIV-1 Seronegative, Herpes Simplex Virus Type 2 Seropositive African Women: A Randomized, Placebo-Controlled Trial. Sexually transmitted diseases 2012; 39(1): 21-4.
56. Lu Y, Hendrix C, Celum C. Acyclovir achieves lower concentration in African HIV, HSV21 women compared to non- African populations, possibly explaining lower herpes suppression. Sex Transm Infect 2011; 87(Suppl_1): A79.
57. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein- D-adjuvant vaccine to prevent genital herpes. The New England journal of medicine [Clinical Trial] 2002; 347(21): 1652-61.
58. Belshe RB, Leone PA, Bernstein DI, et al. Efficacy Results of a Trial of a Herpes Simplex Vaccine N Engl J Med 2012; 366(1): 34-43.
59. Halford WP, Puschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PloS One 2011; 6(3): e17748.
60. Cohen J. Immunology. Painful failure of promising genital herpes vaccine. Science [News] 2010; 330(6002): 304.
61. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329(5996): 1168-74.
62. Andrei G, Lisco A, Vanpouille C, Introini A, et al. Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication. Cell host & microbe 2011; 10(4): 379-89.
63. Microbicide Trials Network. MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women 2011 [updated 12/01/2011]; Available from: http://www.mtnstopshiv.org/node/3909.
64. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126(12): 946-54.
65. Stein DS, Graham NM, Park LP, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Ann Intern Med 1994; 121(2): 100-8.
66. Ioannidis JP, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998; 178(2): 349-59.
67. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS [Review] 2008; 22(16): 2179-85.
68. Lingappa JR, Baeten JM, Wald A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375(9717): 824-33.
69. Reynolds SJ, Makumbi F, Kiwanuka N, et al. Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo-controlled trial in Rakai, Uganda In: Barnabas RV, editor. Seattle: Abstract for presentation at IAS; 2011.
70. [Roxby AC, Drake AL, Ongecha-Owuror F, et al. Peripartum Valacyclovir Improves Markers of HIV-1 Disease Progression in Women Co-infected with HSV-2: A Randomized Trial IAS; July 2011; Rome 2011.
71. Drake AL, Roxby AC, Ongecha-Owuor F, et al. Valacyclovir Suppressive Therapy Reduces Plasma and Breast Milk HIV-1 RNA Levels During Pregnancy and Postpartum: A Randomized Trial. J Infect Dis 2011.
72. Perti T, Baeten J, Diem K, et al. High-dose Valacyclovir Decreases Plasma HIV-1 Levels More than Standard Dose Acyclovir in HIV, HSV-2 positive persons: a Randomized, Crossover Trial July 2011; Montreal 2011.
73. Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C. High-dose Valacyclovir HSV-2 Suppression Results in Greater Reduction in Plasma HIV-1 Levels Compared With Standard Dose Acyclovir Among HIV-1/HSV-2 Coinfected Persons: A Randomized, Crossover Trial. J Infect Dis 2011 Oct 12.
74. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PloS One [Randomized Controlled Trial] 2010; 5(9): e12598.
75. Tanton C, Abu-Raddad LJ, Weiss HA. Time to Refocus on HSV Interventions for HIV Prevention? J Infect Dis 2011; 204(12): 1822-6.
76. [Reynolds SJ, Makumbi F, Kiwanuka N, et al. Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo-controlled trial in Rakai, Uganda. IAS; Rome 2011.
77. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebocontrolled, cross-over trial. J Infect Dis 2008; 198(12): 1804-8.
78. Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009; 23(4): 461-9.
79. Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2- infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008; 49(1): 77-83.
80. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356(8): 790-9.
81. Tanton C, Weiss HA, Rusizoka M, et al. Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial. J Infect Dis 2010; 201(9): 1285-97.
82. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007; 196(10): 1500-8.
83. Cohen MS, Eron JJ, Jr. Aciclovir Treatment for Human Immunodeficiency Virus-1: Is the "Juice Worth the Squeeze?". Sexually Transmitted Diseases 2011; 38(5): 410-2.
84. McMahon MA, Siliciano JD, Lai J, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008; 283(46): 31289-93.
85. Lisco A, Vanpouille C, Tchesnokov EP, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008; 4(3): 260-70.
86. Baeten JM, Lingappa J, Beck I, et al. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. J Infect Dis 2011; 203(1): 117-21.
87. LeGoff J, Tanton C, Delaugerre C, et al. No selection of nucleoside reverse transcriptase inhibitor resistance associated mutations by acyclovir suppressive therapy in herpes simplex virus-2/HIV-1 dually infected persons. AIDS 2010; 24(16): 2595-6.
88. Vickerman P, Devine A, Foss AM, Delany-Moretlwe S, Mayaud P, Meyer-Rath G. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa. Sexually transmitted diseases 2011; 38(5): 401-9.
89. Corbell C, Stergachis A, Ndowa F, Ndase P, Barnes L, Celum C. Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries. Sex Transm Dis 2010; 37(8): 488-93.
90. Kohler P, Chung M, Benki-Nugent S, et al. Free CTX Substantially Improves Retention among ART-ineligible Clients in a Kenyan HIV Treatment Program 2011.
91. [UNAIDS/WHO. UNAIDS Report on the Global AIDS Epidemic: Joint United Nations Programme on HIV/AIDS 2010.
92. Tan DH, Kaul R, Raboud JM, Walmsley SL. No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. AIDS 2011; 25(2): 207-10.
93. Galarraga FS. Reengineering translational science: the time is right. Sci Transl Med 2011; 3(90): 90cm17.
94. Galarraga O, Colchero MA, Wamai RG, Bertozzi SM. HIV prevention cost-effectiveness: a systematic review. BMC Public Health 2009; 9 Suppl 1: S5.
95. WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva: WHO; 2010; Available from: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf